Cerveau Technologies has signed an agreement to provide Roche with the PET radiotracer F-18 MK-6240 for assessing the status and progression of tau neurofibrillary tangles (NFTs) in the brain.
Tau protein NFTs are a hallmark of several neurodegenerative diseases, including Alzheimer's disease. F-18 MK-6240 was developed to measure tau levels of PET scans. Roche will use the investigational tracer to help develop potential therapeutic treatments.
